Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

Duvakitug represents a meaningful opportunity for Sanofi to begin to bring new science and benefit to IBD patients, continuing immunology and far beyond. We saw statistically significant and ...

Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human immunoglobulin G 1(IgG1)-λ2 monoclonal antibody, duvakitug, in treating ...

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 ...

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 ...